Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant glioma
Phase 1
- Conditions
- Malignant Glioma DIPG
- Registration Number
- JPRN-UMIN000013258
- Lead Sponsor
- Osaka university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1)active infectious diseases 2)Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3)Other severe problems unsuitable for this study active infectious diseases 4)Active other cancers except for carcinoma in situ treated completely 5)Past history of Myeloproliferative diseases, MSD 6)Received allogeneic stem cell transplantation 7)Severe Psychological Problems
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One year survival ratio
- Secondary Outcome Measures
Name Time Method Effectiveness using RANO criteria, Safty, immunomonitaring to WT1 peptide